TRA2A

Summary

TRA2A (transformer 2 alpha homolog, HGNC:16645) is a protein-coding gene on chromosome 7p15.3, encoding Transformer-2 protein homolog alpha (Q13595). Sequence-specific RNA-binding protein which participates in the control of pre-mRNA splicing.

This gene is a member of the transformer 2 homolog family and encodes a protein with several RRM (RNA recognition motif) domains. This phosphorylated nuclear protein binds to specific RNA sequences and plays a role in the regulation of pre-mRNA splicing. Alternatively spliced transcript variants have been found for this gene.

Source: NCBI Gene 29896 — RefSeq curated summary.

At a glance

• GWAS associations: 2
• Clinical variants (ClinVar): 50 total
• MANE Select transcript: NM_013293

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:16645
Approved symbol	TRA2A
Name	transformer 2 alpha homolog
Location	7p15.3
Locus type	gene with protein product
Status	Approved
Aliases	htra-2-alpha, AWMS1
Ensembl gene	ENSG00000164548
Ensembl biotype	protein_coding
OMIM	602718
Entrez	29896

Gene structure

Transcript identifiers

Ensembl transcripts: 18 — 9 protein_coding, 4 retained_intron, 3 protein_coding_CDS_not_defined, 2 nonsense_mediated_decay

ENST00000297071, ENST00000392502, ENST00000448549, ENST00000474586, ENST00000475970, ENST00000482395, ENST00000486934, ENST00000490942, ENST00000494255, ENST00000497730, ENST00000538367, ENST00000621813, ENST00000870822, ENST00000870823, ENST00000870824, ENST00000923620, ENST00000923621, ENST00000923622

RefSeq mRNA: 7 — MANE Select: NM_013293 NM_001282757, NM_001282758, NM_001282759, NM_001362759, NM_001362760, NM_001362761, NM_013293

CCDS: CCDS5383, CCDS64609, CCDS75569

Canonical transcript exons

ENST00000297071 — 8 exons

Exon	Start	End
ENSE00001085421	23531789	23531981
ENSE00001085423	23504780	23505569
ENSE00001159675	23506138	23506266
ENSE00001159681	23507420	23507535
ENSE00003538377	23521707	23521840
ENSE00003555723	23516363	23516528
ENSE00003603856	23512894	23513082
ENSE00003677104	23505746	23505813

Expression profiles

Bgee: expression breadth ubiquitous, 294 present calls, max score 98.53.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 61.9894 / max 862.1093, expressed in 1820 samples.

FANTOM5 promoters (4 alternative TSS)

Promoter ID	TPM avg	Samples expressed
83127	48.0654	1817
83122	7.4557	1657
83128	5.7102	1711
83123	0.7582	373

Top tissues by expression

300 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
right uterine tube	UBERON:0001302	98.53	gold quality
buccal mucosa cell	CL:0002336	98.22	gold quality
right ovary	UBERON:0002118	98.18	gold quality
ganglionic eminence	UBERON:0004023	98.13	gold quality
left ovary	UBERON:0002119	98.12	gold quality
ventricular zone	UBERON:0003053	98.01	gold quality
endocervix	UBERON:0000458	97.93	gold quality
sural nerve	UBERON:0015488	97.81	gold quality
body of uterus	UBERON:0009853	97.76	gold quality
lower esophagus mucosa	UBERON:0035834	97.62	gold quality
vagina	UBERON:0000996	97.56	gold quality
right lobe of thyroid gland	UBERON:0001119	97.56	gold quality
skin of abdomen	UBERON:0001416	97.52	gold quality
cortical plate	UBERON:0005343	97.52	gold quality
left uterine tube	UBERON:0001303	97.39	gold quality
ectocervix	UBERON:0012249	97.38	gold quality
granulocyte	CL:0000094	97.32	gold quality
tibial nerve	UBERON:0001323	97.27	gold quality
left lobe of thyroid gland	UBERON:0001120	97.25	gold quality
minor salivary gland	UBERON:0001830	97.25	gold quality
monocyte	CL:0000576	97.18	gold quality
adenohypophysis	UBERON:0002196	97.16	gold quality
cerebellar hemisphere	UBERON:0002245	97.15	gold quality
cerebellar cortex	UBERON:0002129	97.13	gold quality
muscle layer of sigmoid colon	UBERON:0035805	97.00	gold quality
C1 segment of cervical spinal cord	UBERON:0006469	96.99	gold quality
mononuclear cell	CL:0000842	96.97	gold quality
spleen	UBERON:0002106	96.94	gold quality
small intestine Peyer’s patch	UBERON:0003454	96.91	gold quality
body of pancreas	UBERON:0001150	96.90	gold quality

Single-cell (SCXA)

Detected in 6 experiment(s), a significant marker in 2.

Experiment	Marker?	Max mean expression
E-MTAB-7051	yes	1262.94
E-GEOD-76312	no	3804.33
E-GEOD-93593	no	6.84
E-MTAB-9801	no	5.19
E-MTAB-9543	no	2.41
E-ANND-3	no	0.00

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

66 targeting TRA2A, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-LET-7A-3P	100.00	74.03	3932
HSA-LET-7B-3P	100.00	74.08	3913
HSA-LET-7F-1-3P	100.00	74.02	3928
HSA-MIR-98-3P	100.00	74.08	3907
HSA-MIR-5692A	100.00	74.40	6850
HSA-MIR-196A-1-3P	99.99	72.15	2772
HSA-MIR-4282	99.99	75.36	6408
HSA-MIR-4803	99.98	71.99	3117
HSA-MIR-548P	99.98	72.25	3784
HSA-MIR-607	99.97	73.62	5593
HSA-MIR-3065-5P	99.97	71.56	3281
HSA-MIR-302C-5P	99.97	72.56	3642
HSA-MIR-3148	99.97	75.06	6478
HSA-MIR-3658	99.96	73.87	4379
HSA-MIR-548AT-5P	99.96	70.83	2666
HSA-MIR-2110	99.96	66.68	1930
HSA-MIR-4666A-3P	99.96	71.71	3434
HSA-MIR-144-3P	99.94	73.98	2698
HSA-MIR-381-3P	99.93	71.87	2854
HSA-MIR-300	99.92	71.76	2856
HSA-MIR-10527-5P	99.91	72.28	3754
HSA-MIR-3529-3P	99.90	73.55	3045
HSA-MIR-3671	99.90	73.04	3897
HSA-MIR-374A-5P	99.90	71.34	2923
HSA-MIR-374B-5P	99.90	69.98	2734
HSA-MIR-548E-5P	99.89	72.73	4486
HSA-MIR-95-5P	99.89	72.17	3973
HSA-MIR-4698	99.84	71.41	4303
HSA-MIR-576-5P	99.84	70.46	2582
HSA-MIR-4420	99.82	70.08	1624

Literature-anchored findings (GeneRIF, showing 8)

• Expression of tumor-promoting Cyr61 is regulated by hTRA2-beta1 and acidosis. (PMID:21447598)
• findings show the inclusion of both HIV-1 exon 3 and vpr mRNA processing is promoted by an exonic splicing enhancer (ESEvpr) localized between exonic splicing silencer ESSV and 5’ss D3; the ESEvpr sequence was found to be bound by members of the Tra2 protein family (PMID:23255807)
• Overexpression of either Tra2alpha or Tra2beta results in a marked reduction in HIV-1 Gag/ Env expression. (PMID:25970345)
• our findings suggest that paclitaxel targets the TRA2A-RSRC2 splicing pathway, and deregulated TRA2A and RSRC2 expression may confer paclitaxel resistance. In addition, our study demonstrates that expression of TRA2A in conjunction with RSRC2 may provide valuable molecular biomarker evidence for triple-negative breast cancer (TNBC)clinical treatment decisions and patient outcome (PMID:28416606)
• Overexpression of TRA2A in glioma SHG44 cell lines promoted the tumor cells proliferation, migration, invasion and epithelial mesenchymal transition (EMT), while, knockdown of TRA2A showed the opposite effect. (PMID:30367895)
• we knocked down three regulators respectively and found two of them (TRA2A and CAPRIN1) selectively promoted the methylations of the m6A sites co-localized with their binding targets on RNAs through physical interactions with the m6A writers. Knockdown of TRA2A increased the stabilities of the RNAs with TRA2A bound near the m6A sites and decreased the viability of cells (PMID:31912146)
• TRA2A-induced upregulation of LINC00662 regulates blood-brain barrier permeability by affecting ELK4 mRNA stability in Alzheimer’s microenvironment. (PMID:32372707)
• Transformer 2 alpha homolog is a downstream gene of hypoxia-inducible factor 1 subunit alpha and is involved in the progression of pancreatic cancer. (PMID:35635094)

Cross-species orthologs

5 orthologs

Organism	Symbol	Gene ID
danio_rerio	tra2a	ENSDARG00000007863
mus_musculus	Tra2a	ENSMUSG00000029817
rattus_norvegicus	Tra2a	ENSRNOG00000009156
drosophila_melanogaster	tra2	FBGN0003742
caenorhabditis_elegans		WBGENE00004705

Paralogs (1): TRA2B (ENSG00000136527)

Protein

Protein identifiers

Transformer-2 protein homolog alpha — Q13595 (reviewed: Q13595)

Alternative names: Transformer-2 protein homolog A

All UniProt accessions (4): A0A8J9ASM4, Q13595, F8WEH2, Q549U1

UniProt curated annotations — full annotation on UniProt →

Function. Sequence-specific RNA-binding protein which participates in the control of pre-mRNA splicing.

Subunit / interactions. Binds to A3 enhancer proteins SRp75, SRp55, SRp40 and SRp30. Interacts with ILDR1 (via C-terminus) and ILDR2.

Subcellular location. Nucleus.

Post-translational modifications. Phosphorylated in the RS domains.

Similarity. Belongs to the splicing factor SR family.

Isoforms (4)

UniProt ID	Names	Canonical?
Q13595-1	Long	yes
Q13595-2	Short
Q13595-3	3
Q13595-4	4

RefSeq proteins (7): NP_001269686, NP_001269687, NP_001269688, NP_001349688, NP_001349689, NP_001349690, NP_037425* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR000504	RRM_dom	Domain
IPR012677	Nucleotide-bd_a/b_plait_sf	Homologous_superfamily
IPR035979	RBD_domain_sf	Homologous_superfamily
IPR050441	RBM	Family

Pfam: PF00076

UniProt features (31 total): modified residue 14, compositionally biased region 5, splice variant 4, region of interest 4, initiator methionine 1, chain 1, domain 1, cross-link 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q13595-F1	58.36	0.21

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (15): 2, 2, 14, 24, 82, 84, 86, 88, 96, 98, 202, 204, 232, 236, 198

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 189 (showing top): FLECHNER_PBL_KIDNEY_TRANSPLANT_REJECTED_VS_OK_UP, GRAESSMANN_APOPTOSIS_BY_DOXORUBICIN_UP, YY1_Q6, ONKEN_UVEAL_MELANOMA_UP, FOSTER_TOLERANT_MACROPHAGE_UP, DOANE_RESPONSE_TO_ANDROGEN_DN, GOBP_RNA_SPLICING, SCHLOSSER_SERUM_RESPONSE_DN, NKX22_01, GATA2_01, MORF_PML, SPIELMAN_LYMPHOBLAST_EUROPEAN_VS_ASIAN_UP, MORF_PDPK1, MORF_IKBKG, KAYO_AGING_MUSCLE_UP

GO Biological Process (4): mRNA splicing, via spliceosome (GO:0000398), positive regulation of mRNA splicing, via spliceosome (GO:0048026), mRNA processing (GO:0006397), RNA splicing (GO:0008380)

GO Molecular Function (3): RNA binding (GO:0003723), nucleic acid binding (GO:0003676), protein binding (GO:0005515)

GO Cellular Component (4): nucleus (GO:0005634), nucleoplasm (GO:0005654), spliceosomal complex (GO:0005681), nucleolus (GO:0005730)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
RNA processing	2
binding	2
nuclear lumen	2
RNA splicing, via transesterification reactions with bulged adenosine as nucleophile	1
mRNA processing	1
mRNA splicing, via spliceosome	1
positive regulation of RNA splicing	1
regulation of mRNA splicing, via spliceosome	1
positive regulation of mRNA processing	1
mRNA metabolic process	1
nucleic acid binding	1
intracellular membrane-bounded organelle	1
cellular anatomical structure	1
nuclear protein-containing complex	1
ribonucleoprotein complex	1
intracellular membraneless organelle	1

Protein interactions and networks

STRING

2964 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
TRA2A	SRSF1	Q07955	850
TRA2A	SRSF7	Q16629	701
TRA2A	SRSF10	O75494	699
TRA2A	SRSF3	P23152	646
TRA2A	HNRNPK	P61978	641
TRA2A	HNRNPM	P52272	637
TRA2A	SRSF9	Q13242	613
TRA2A	SRSF4	Q08170	610
TRA2A	ILDR2	Q71H61	581
TRA2A	SRSF6	Q13247	572
TRA2A	ILDR1	Q86SU0	571
TRA2A	SRSF11	Q05519	565
TRA2A	RBM15	Q96T37	543
TRA2A	RSRC2	Q7L4I2	541
TRA2A	PUM2	Q8TB72	522

IntAct

130 interactions, top by confidence:

A	B	Type	Score
CDK8	MED19	psi-mi:“MI:0914”(association)	0.850
TRA2A	RNPS1	psi-mi:“MI:0915”(physical association)	0.740
SRPK2	TRA2A	psi-mi:“MI:0217”(phosphorylation reaction)	0.690
TRA2A	YWHAG	psi-mi:“MI:0915”(physical association)	0.670
SNRNP70	GEMIN2	psi-mi:“MI:0914”(association)	0.640
XPOT	TRA2A	psi-mi:“MI:0915”(physical association)	0.560
TRA2A	MAGOHB	psi-mi:“MI:0915”(physical association)	0.560
YTHDC1	TRA2A	psi-mi:“MI:0915”(physical association)	0.550
SNIP1	CASC3	psi-mi:“MI:0914”(association)	0.530
GSPT2	IGF2BP3	psi-mi:“MI:0914”(association)	0.530
SNRNP70	GTPBP1	psi-mi:“MI:0914”(association)	0.530
TRA2A	U2SURP	psi-mi:“MI:0915”(physical association)	0.520
CPSF6	DDX39A	psi-mi:“MI:0914”(association)	0.480
U2AF2	U2SURP	psi-mi:“MI:0914”(association)	0.480
TRA2A	CDK6	psi-mi:“MI:0217”(phosphorylation reaction)	0.440
FUS	DDX3X	psi-mi:“MI:0914”(association)	0.430
LBP	TRA2A	psi-mi:“MI:0915”(physical association)	0.370
TRA2A	NXF1	psi-mi:“MI:0915”(physical association)	0.370
TRA2A	PPP1CC	psi-mi:“MI:0915”(physical association)	0.370
TRA2A	SMAP	psi-mi:“MI:0915”(physical association)	0.370
TRA2A	CDK2AP2	psi-mi:“MI:0915”(physical association)	0.370
TRA2A	CRABP1	psi-mi:“MI:0915”(physical association)	0.370
NUDT21	TRA2A	psi-mi:“MI:0915”(physical association)	0.370
TRA2A	SELENBP1	psi-mi:“MI:0915”(physical association)	0.370
TRA2A	TNNT1	psi-mi:“MI:0915”(physical association)	0.370
DHX15	TRA2A	psi-mi:“MI:0915”(physical association)	0.370
FEN1	CHPF2	psi-mi:“MI:0914”(association)	0.350
CDK2	BLTP3B	psi-mi:“MI:0914”(association)	0.350
DDX41	DDX39A	psi-mi:“MI:0914”(association)	0.350

BioGRID (539): TRA2A (Affinity Capture-MS), TRA2A (Affinity Capture-MS), TRA2A (Affinity Capture-MS), TRA2A (Affinity Capture-MS), TRA2A (Affinity Capture-MS), TRA2A (Affinity Capture-MS), TRA2A (Affinity Capture-MS), LARP7 (Affinity Capture-MS), SRRM1 (Affinity Capture-MS), MRPS9 (Affinity Capture-MS), MRPS26 (Affinity Capture-MS), THRAP3 (Affinity Capture-MS), LUC7L2 (Affinity Capture-MS), LUC7L (Affinity Capture-MS), ZNF768 (Affinity Capture-MS)

ESM2 similar proteins: A2RVS6, F4JHI7, O22315, O75494, O81126, O81127, P30352, P84103, P84104, P92964, P92965, P92966, Q01130, Q06A98, Q07955, Q09511, Q0VCY7, Q10021, Q13242, Q13595, Q16629, Q18409, Q23120, Q23121, Q3MHR5, Q3SZR8, Q3T106, Q3YLA6, Q5PPI1, Q5R1W5, Q5R7H2, Q62093, Q69KL9, Q6DII2, Q6K4N0, Q6K9C3, Q6NYA0, Q6PDM2, Q6PDU1, Q6PFR5

Diamond homologs: A1C646, A1DGS2, A2A5N3, A2Q848, A2R7Z2, A3GGU2, A4QUF0, A4RHN3, A5DNX9, A5E1Z4, A6SGN8, A6ZZ25, A7EWN6, A7SKE9, A7TFW4, A8NS61, A8WLV5, B0VZS1, B0XS28, B3MSP2, B3MYX2, B3NYY7, B3P935, B4G3E2, B4GUY6, B4I9X1, B4IIC7, B4J4G8, B4JXU2, B4K7S5, B4L710, B4LVR8, B4MA85, B4N1L0, B4NFY1, B4NTY9, B4PP90, B4Q0Y7, B4QS37, C8V330

SIGNOR signaling

0 interactions.

Enriched among interaction partners

Reactome pathways and GO biological processes over-represented among this gene’s 156 IntAct physical interaction partners (hypergeometric vs the genome-wide background, BH-FDR, gene-set size 15–500, ranked by fold). A functional readout of the neighbourhood — distinct from this gene’s own memberships above, and biased toward well-studied / hub proteins, so read it as themes rather than proof.

Reactome pathways:

Pathway	Partners	Fold	FDR
Transport of Mature Transcript to Cytoplasm	7	24.0×	7e-07
mRNA 3’-end processing	12	21.3×	2e-11
RNA Polymerase II Transcription Termination	10	19.8×	4e-09
mRNA Splicing	19	18.8×	3e-17
Transport of Mature mRNA derived from an Intron-Containing Transcript	12	16.5×	5e-10
mRNA Polyadenylation	20	15.8×	1e-16
Processing of Capped Intron-Containing Pre-mRNA	21	15.5×	3e-17
mRNA Splicing - Major Pathway	27	13.3×	2e-20

GO biological processes:

GO term	Partners	Fold	FDR
negative regulation of mRNA splicing, via spliceosome	7	40.0×	9e-08
mRNA splice site recognition	5	29.9×	6e-05
spliceosomal complex assembly	5	22.5×	2e-04
nuclear-transcribed mRNA catabolic process, nonsense-mediated decay	6	21.0×	4e-05
regulation of alternative mRNA splicing, via spliceosome	11	20.1×	3e-09
mRNA export from nucleus	8	17.6×	3e-06
mRNA splicing, via spliceosome	21	14.3×	1e-15
mitophagy	6	14.2×	3e-04

Disease & clinical

Clinical variants and AI predictions

ClinVar

50 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	33
Likely benign	0
Benign	0

Top pathogenic / likely-pathogenic (0)

SpliceAI

1091 predictions. Top by Δscore:

Variant	Effect	Δscore
7:23505742:ATAC:A	donor_loss	1.0000
7:23505743:TACT:T	donor_loss	1.0000
7:23505744:A:AC	donor_gain	1.0000
7:23505744:ACT:A	donor_loss	1.0000
7:23505745:C:CC	donor_gain	1.0000
7:23505811:CTT:C	acceptor_gain	1.0000
7:23505814:C:CC	acceptor_gain	1.0000
7:23506134:TTA:T	donor_loss	1.0000
7:23506135:TAC:T	donor_loss	1.0000
7:23506136:A:AT	donor_loss	1.0000
7:23506137:C:CA	donor_loss	1.0000
7:23506262:CACTA:C	acceptor_gain	1.0000
7:23506264:CTA:C	acceptor_gain	1.0000
7:23506265:TA:T	acceptor_gain	1.0000
7:23506267:C:CC	acceptor_gain	1.0000
7:23506270:C:CT	acceptor_gain	1.0000
7:23506277:A:AC	acceptor_gain	1.0000
7:23507409:TGA:T	donor_gain	1.0000
7:23507418:A:AC	donor_gain	1.0000
7:23507419:C:CG	donor_gain	1.0000
7:23507419:CT:C	donor_gain	1.0000
7:23507419:CTGA:C	donor_gain	1.0000
7:23507419:CTGAG:C	donor_gain	1.0000
7:23507443:G:A	donor_gain	1.0000
7:23512895:T:TA	donor_gain	1.0000
7:23513079:TTGC:T	acceptor_gain	1.0000
7:23513081:GC:G	acceptor_gain	1.0000
7:23513082:CC:C	acceptor_gain	1.0000
7:23513082:CCTAT:C	acceptor_loss	1.0000
7:23513083:C:CC	acceptor_gain	1.0000

AlphaMissense

1765 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
7:23507432:C:T	G210D	1.000
7:23507433:C:A	G210C	1.000
7:23507433:C:G	G210R	1.000
7:23507435:A:G	M209T	1.000
7:23507438:T:C	Y208C	1.000
7:23507439:A:C	Y208D	1.000
7:23507439:A:G	Y208H	1.000
7:23507439:A:T	Y208N	1.000
7:23507444:C:A	G206V	1.000
7:23507444:C:T	G206D	1.000
7:23507445:C:A	G206C	1.000
7:23507445:C:G	G206R	1.000
7:23507447:G:T	P205Q	1.000
7:23507448:G:A	P205S	1.000
7:23507458:G:C	H201Q	1.000
7:23507458:G:T	H201Q	1.000
7:23507459:T:C	H201R	1.000
7:23507460:G:C	H201D	1.000
7:23507460:G:T	H201N	1.000
7:23507471:G:A	T197I	1.000
7:23507474:A:T	I196K	1.000
7:23507477:G:A	S195F	1.000
7:23507477:G:T	S195Y	1.000
7:23507483:T:A	D193V	1.000
7:23507484:C:G	D193H	1.000
7:23507486:A:T	V192E	1.000
7:23507489:C:G	R191P	1.000
7:23507490:G:C	R191G	1.000
7:23507492:A:C	I190S	1.000
7:23507492:A:G	I190T	1.000

dbSNP variants (sampled 300 via entrez): RS1000039298 (7:23519949 T>C), RS1000208761 (7:23531812 C>T), RS1000308887 (7:23504299 GTC>G), RS1000326273 (7:23526332 G>A), RS1000495848 (7:23520096 A>G), RS1000509386 (7:23506492 C>G), RS1000693804 (7:23511111 C>T), RS1000826022 (7:23524881 AG>A), RS1000882055 (7:23514037 G>A), RS1001144175 (7:23510307 A>T), RS1001147068 (7:23511264 G>A), RS1001196329 (7:23510519 G>A), RS1001259861 (7:23505064 C>A,G), RS1001555418 (7:23526498 T>C), RS1001610065 (7:23532217 C>T)

Disease associations

OMIM: gene MIM:602718 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

2 associations (top):

Study	Trait	p-value
GCST012227_110	Hip circumference adjusted for BMI	2.000000e-09
GCST012227_111	Hip circumference adjusted for BMI	2.000000e-09

EFO canonical traits (1, from GWAS)

EFO ID	Trait name
EFO:0008039	BMI-adjusted hip circumference

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

64 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Valproic Acid	affects expression, decreases expression	5
bisphenol A	decreases expression	2
Arsenic	decreases expression, affects cotreatment, affects splicing, increases abundance	2
Cisplatin	affects cotreatment, decreases expression, increases expression	2
Selenium	decreases expression, increases expression	2
7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide	increases expression	2
Cadmium Chloride	decreases expression, increases expression	2
aristolochic acid I	decreases expression	1
3-((6-(2-methoxyphenyl)pyrimidin-4-yl)amino)phenyl)methane sulfonamide	affects splicing	1
FR900359	affects phosphorylation	1
TAK-243	decreases sumoylation	1
graphene oxide	decreases expression	1
dicrotophos	decreases expression	1
2,4,6-tribromophenol	decreases expression	1
testosterone enanthate	affects expression	1
methylmercuric chloride	increases expression	1
triphenyl phosphate	affects expression	1
testosterone undecanoate	affects cotreatment, decreases expression	1
decabromobiphenyl ether	decreases expression	1
trichostatin A	increases expression	1
zinc chloride	decreases expression	1
sodium arsenite	increases abundance, decreases expression, affects cotreatment, affects splicing	1
tetrabromobisphenol A	decreases expression	1
coumarin	increases phosphorylation	1
4-phenylbutyric acid	decreases expression	1
abrine	increases expression	1
2,2’,4,4’-tetrabromodiphenyl ether	decreases expression	1
pentabrominated diphenyl ether 100	decreases expression	1
hexabrominated diphenyl ether 153	decreases expression	1
jinfukang	affects cotreatment, decreases expression	1

Cellosaurus cell lines

3 cell lines: 3 cancer cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_TT52	HAP1 TRA2A (-) 1	Cancer cell line	Male
CVCL_XU67	HAP1 TRA2A (-) 2	Cancer cell line	Male
CVCL_XU68	HAP1 TRA2A (-) 3	Cancer cell line	Male

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.